Cargando…

Improved pulmonary function following pirfenidone treatment in a patient with progressive interstitial lung disease associated with systemic sclerosis

Pirfenidone is an anti-fibrotic drug which has been approved for the management of patients with Idiopathic Pulmonary Fibrosis (IPF). However, its role in interstitial lung disease (ILD) due to other causes such as systemic sclerosis (SSc) is not clear. We present a case of a patient with SSc associ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Udwadia, Zarir F., Mullerpattan, Jai B., Balakrishnan, Canchi, Richeldi, Luca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2015
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4298919/ https://www.ncbi.nlm.nih.gov/pubmed/25624597 http://dx.doi.org/10.4103/0970-2113.148451

Ejemplares similares

Tropical pulmonary eosinophilia - A review
por: Mullerpattan, Jai B., et al.
Publicado: (2013)

Post-COVID lung fibrosis: The tsunami that will follow the earthquake
por: Udwadia, Zarir F, et al.
Publicado: (2021)

Use of nintedanib in patients with idiopathic pulmonary fibrosis: Initial Indian experience
por: Mullerpattan, Jai B, et al.
Publicado: (2019)

Home spirometry to assess efficacy of pirfenidone in progressive unclassifiable interstitial lung disease: better the devil you know than the devil you don’t
por: Sgalla, Giacomo, et al.
Publicado: (2020)

Possible impact of the standardized Category IV regimen on multidrug-resistant tuberculosis patients in Mumbai
por: Udwadia, Zarir F, et al.
Publicado: (2016)

Effective use of telemedicine in Mumbai with a cohort of extensively drug-resistant “XDR” tuberculosis patients on bedaquiline during COVID-19 pandemic
por: Udwadia, Zarir F., et al.
Publicado: (2021)

Who will teach the teachers: An analysis of the inhaler technique of Indian patients and health care providers in a tertiary health care centre
por: Mullerpattan, Jai Bharat, et al.
Publicado: (2016)

Editorial: Interstitial Lung Disease Around the World
por: Wijsenbeek, Marlies, et al.
Publicado: (2022)

Idiopathic pulmonary fibrosis in BRIC countries: the cases of Brazil, Russia, India, and China
por: Richeldi, Luca, et al.
Publicado: (2015)

Correction to: Idiopathic pulmonary fibrosis in BRIC countries: the cases of Brazil, Russia, India, and China
por: Richeldi, Luca, et al.
Publicado: (2021)

Interstitial lung abnormalities a risk factor for rheumatoid arthritis interstitial lung disease progression: what's new
por: Leone, Paolo Maria, et al.
Publicado: (2020)

Is pirfenidone ready for use in non-idiopathic pulmonary fibrosis interstitial lung diseases?
por: Dhooria, Sahajal, et al.
Publicado: (2015)

The impact of COVID-19 on patients with preexisting interstitial lung disease: High mortality in these high-risk patients
por: Udwadia, Zarir Farokh, et al.
Publicado: (2021)

Pirfenidone in patients with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis
por: Li, Ting, et al.
Publicado: (2016)

Severe interstitial lung disease persisting 2 years post-COVID-19 despite anti-fibrotic therapy
por: Udwadia, Zarir F., et al.
Publicado: (2022)

New Era of Management Concept on Pulmonary Fibrosis with Revisiting Framework of Interstitial Lung Diseases
por: Azuma, Arata, et al.
Publicado: (2020)

Fibrotic interstitial lung disease occurring as sequelae of COVID-19 pneumonia despite concomitant steroids
por: Udwadia, Zarir Farokh, et al.
Publicado: (2021)

Bronchoalveolar lavage contamination by sterile containers: A unique and unrecognized cause of a false-positive galactomannan
por: Kathar, Sushil Shriram, et al.
Publicado: (2017)

Effects of pirfenidone on renal function in patients with interstitial pneumonia
por: Matsumoto, Jun, et al.
Publicado: (2021)

Pirfenidone exacerbates Th2-driven vasculopathy in a mouse model of systemic sclerosis-associated interstitial lung disease
por: Birnhuber, Anna, et al.
Publicado: (2022)

A case report: The efficacy of pirfenidone in a Chinese patient with progressive systemic sclerosis-associated interstitial lung disease: A CARE-compliant article
por: Huang, Hui, et al.
Publicado: (2016)

Efficacy of Pirfenidone and Nintedanib in Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis: A Systematic Review
por: Amati, Francesco, et al.
Publicado: (2023)

Subclinical Interstitial Lung Abnormalities: Lumping and Splitting Revisited
por: Walsh, Simon L. F., et al.
Publicado: (2019)

COVID-19 and Interstitial Lung Disease: Keep Them Separate
por: Podolanczuk, Anna J., et al.
Publicado: (2020)

Factors Affecting Best-Tolerated Dose of Pirfenidone in Patients with Fibrosing Interstitial Lung Disease
por: Mandovra, Neha P., et al.
Publicado: (2023)

Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis
por: Maryandyshev, Andrey, et al.
Publicado: (2017)

The Impact of Progressive Pulmonary Fibrosis in Systemic Sclerosis–Associated Interstitial Lung Disease
por: Martín-López, María, et al.
Publicado: (2023)

Oxaliplatin-induced lung fibrosis
por: Shah, Arpan, et al.
Publicado: (2009)

Pirfenidone for the treatment of interstitial lung disease associated to rheumatoid arthritis: a new scenario is coming?
por: Cassone, Giulia, et al.
Publicado: (2020)

Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
por: Cottin, Vincent, et al.
Publicado: (2021)

Pirfenidone treatment of idiopathic pulmonary fibrosis
por: Gan, Ye, et al.
Publicado: (2011)

Role of pirfenidone in the management of pulmonary fibrosis
por: Meyer, Keith C, et al.
Publicado: (2017)

Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond
por: Aimo, Alberto, et al.
Publicado: (2022)

Pulmonary function tests as outcomes for systemic sclerosis interstitial lung disease
por: Caron, Melissa, et al.
Publicado: (2018)

Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: design of a double-blind, randomised, placebo-controlled phase II trial
por: Maher, Toby M, et al.
Publicado: (2018)

The 2018 Diagnosis of Idiopathic Pulmonary Fibrosis Guidelines: Surgical Lung Biopsy for Radiological Pattern of Probable Usual Interstitial Pneumonia Is Not Mandatory
por: Raghu, Ganesh, et al.
Publicado: (2019)

Case Report: Successful Treatment of Refractory Interstitial Lung Disease With Cyclosporine A and Pirfenidone in a Child With SLE
por: Deng, Linxia, et al.
Publicado: (2021)

Pirfenidone in Unclassifiable Interstitial Lung Disease: A Subgroup Analysis by Concomitant Mycophenolate Mofetil and/or Previous Corticosteroid Use
por: Kreuter, Michael, et al.
Publicado: (2021)

Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database
por: Hoffmann-Vold, Anna-Maria, et al.
Publicado: (2021)

The role of pirfenidone in the treatment of idiopathic pulmonary fibrosis
por: Cottin, Vincent
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_pe241i7qg6m3iasdsrck5542u7